Advocacy intelligence hub — real-time data for patient organizations
Nanfang Hospital, Southern Medical University — NA
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — EARLY_PHASE1
Jacqueline Garcia, MD — PHASE1
Newave Pharmaceutical Inc — PHASE1
Kalydeco: FDA approved
treatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data
City of Hope Medical Center — PHASE2
Dartmouth-Hitchcock Medical Center — PHASE3
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Kalydeco
Vertex Pharmaceuticals Incorporated
Jorge Cortes, MD
UT MD Anderson Cancer Center
Ryotaro Nakamura
City of Hope Medical Center
📍 Duarte, California
Damiano Rondelli, MD, M.D
University of Illinois at Chicago
📍 CHICAGO, IL
Andrew Rezvani, MD
Stanford University
📍 STANFORD, CA
Aref Al-Kali, M.D
Mayo Clinic Cancer Center LAO
📍 ROCHESTER, MN
Andrea Bacigalupo
Unit for Hematology and BMT, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy